Rafferty Asset Management, LLC Esperion Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.46 - $7.3 $3,498 - $17,490	2,396 Added 22.0%	13,287 $21,000
Q4 2022 Feb 13, 2023	BUY	$5.09 - $8.5 $55,435 - $92,573	10,891 New	10,891 $67,000
Q1 2022 May 13, 2022	SELL	$3.34 - $5.56 $114,652 - $190,858	-34,327 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$4.81 - $11.92 $165,112 - $409,177	34,327 New	34,327 $172,000
Q3 2021 Nov 10, 2021	SELL	$11.34 - $21.37 $1.12 Million - $2.11 Million	-98,918 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$19.4 - $28.71 $211,401 - $312,852	-10,897 Reduced 9.92%	98,918 $2.09 Million
Q1 2021 May 10, 2021	BUY	$25.12 - $36.89 $2.01 Million - $2.95 Million	79,954 Added 267.75%	109,815 $3.08 Million
Q4 2020 Feb 10, 2021	SELL	$24.2 - $35.76 $546,315 - $807,282	-22,575 Reduced 43.05%	29,861 $776,000
Q3 2020 Nov 13, 2020	BUY	$31.18 - $52.71 $950,241 - $1.61 Million	30,476 Added 138.78%	52,436 $1.95 Million
Q2 2020 Aug 07, 2020	BUY	$30.04 - $51.31 $659,678 - $1.13 Million	21,960 New	21,960 $1.13 Million
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $860,408 - $2.32 Million	-31,356 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$35.4 - $59.82 $2.23 Million - $3.77 Million	-63,078 Reduced 66.8%	31,356 $1.87 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $40,502 - $55,847	1,175 Added 1.26%	94,434 $3.46 Million
Q2 2019 Aug 09, 2019	BUY	$40.1 - $52.33 $982,008 - $1.28 Million	24,489 Added 35.61%	93,259 $4.34 Million
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $2.76 Million - $3.68 Million	68,770 New	68,770 $2.76 Million

208

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.